Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/5/2020 12:23:15 PM - Followers: 102 - Board type: Free - Posts Today: 3


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

ZYNE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annua... 02/20/2020 08:30:10 AM
ZYNE News: Statement of Ownership (sc 13g) 02/11/2020 04:41:43 PM
ZYNE News: Statement of Ownership (sc 13g) 02/07/2020 08:52:45 AM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 02/03/2020 04:38:12 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 02/03/2020 04:36:23 PM
PostSubject
#2259   Focus on the MOST important 2 things dhbuzz 04/05/20 12:23:15 PM
#2258   Ouch The Registrant previously filed the Registration Statements Grim Reaper 04/05/20 10:32:24 AM
#2257   Do they make a profit? Grim Grim Reaper 04/05/20 10:30:18 AM
#2256   I was thinking the same thing. If there BrownCornSnake 04/04/20 11:10:01 PM
#2255   BCS. I don't know this for sure,but dhbuzz 04/03/20 11:42:20 AM
#2254   Someone on yahoo board posted info saying dhbuzz 04/03/20 09:38:35 AM
#2253   With Covid 19 are the trials continuing. Does BrownCornSnake 04/03/20 09:24:37 AM
#2252   I'm hopping that's the question dhbuzz 04/02/20 08:22:41 PM
#2251   Whyyyyy mwhite57 04/01/20 03:39:12 PM
#2250   It has been impressive dhbuzz 03/21/20 12:14:26 PM
#2249   Short volume is lowest in months. Been Stockfun1 03/20/20 10:54:36 AM
#2248   I can only interpret that post as dhbuzz 03/17/20 05:30:44 PM
#2247   And there is it... Smh mwhite57 03/16/20 05:49:03 PM
#2246   To buy or not to buy.... Think she mwhite57 03/13/20 12:23:07 PM
#2245   I have a looooooooong memory,I remember someone post dhbuzz 03/12/20 09:16:46 PM
#2244   "PLAY'ER' = FESS AND CLAY TURDER. dhbuzz 03/12/20 09:12:52 PM
#2243   Yea fress we all realize that, dhbuzz 03/12/20 09:09:37 PM
#2242   Hi Brown cs,good to hear from you. dhbuzz 03/11/20 10:07:16 PM
#2241   Mine too. Just a matter of time now. BrownCornSnake 03/11/20 02:04:51 PM
#2240   My fav. part... dhbuzz 03/11/20 10:09:11 AM
#2239   https://zynerba.com/zynerba-pharmaceuticals-reports-fourth-quarter-and-year-end- dhbuzz 03/11/20 09:48:18 AM
#2238   Id like to see what cash on hand is.eom dhbuzz 03/11/20 09:19:10 AM
#2237   Anyone have a link to dhbuzz 03/11/20 09:15:01 AM
#2236   Get your little fanny back up there aove dhbuzz 03/10/20 11:35:14 AM
#2235   https://finance.yahoo.com/news/zynerba-pharmaceuticals-reports-fourth-quarter-10 dhbuzz 03/10/20 09:05:24 AM
#2234   I’m in let’s head to double digits !!! StockNinja33 03/05/20 11:37:04 AM
#2233   Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment Fress 03/05/20 04:47:42 AM
#2232   ANALYST Coverage average price for ZYNE $17.83 Fress 03/04/20 09:48:37 PM
#2231   Amen to that,I see fress has shown back dhbuzz 03/04/20 07:00:32 PM
#2230   Short volume ratio down to 18%. Lowest Stockfun1 03/04/20 12:08:48 PM
#2229   ZYNE trading under the 50 day moving average Fress 03/03/20 10:11:41 AM
#2228   Just sharing a tad more info on ZLDA.Out dhbuzz 02/29/20 12:53:02 PM
#2227   Go back in time to 2010 dhbuzz 02/27/20 09:19:33 AM
#2226   I certainly do Stocfor fun,I've made many post dhbuzz 02/27/20 08:13:27 AM
#2225   Stockfun, I could be wrong of course, but lumpy9200 02/27/20 08:12:33 AM
#2224   Strong buy recommendations, New patent and completion of Stockfun1 02/27/20 07:46:34 AM
#2223   Can someone share with me how we can Stockfun1 02/27/20 07:37:45 AM
#2222   I'm with you on the Coronavirus, and also lumpy9200 02/26/20 08:01:52 PM
#2221   I support ZYNE but Corona virus And Bernie Fress 02/26/20 06:37:02 PM
#2220   I missed seeing that! That's great news. Thanks lumpy9200 02/25/20 07:59:57 PM
#2219   Nice! Thanks iluvtofu. dhbuzz 02/25/20 11:50:29 AM
#2218   Looks like the patent may have given us iluvtofu 02/25/20 11:40:38 AM
#2217   Came across this today, dhbuzz 02/21/20 11:01:29 AM
#2216   https://finance.yahoo.com/news/zynerba-pharmaceuticals-announces-presentations-a dhbuzz 02/20/20 08:40:25 AM
#2215   ZYNE Analyst Price Target $19.75 on TipRanks Smart Stockfun1 02/20/20 07:42:48 AM
#2214   Good to see ZYNE hold most of its Stockfun1 02/20/20 07:34:48 AM
#2213   &^%%<(&^$@!<(*(&^@!!!!!!!!!!!!!!!! dhbuzz 02/19/20 08:57:29 PM
#2212   Good to see an up day,and above average volume. dhbuzz 02/18/20 06:35:10 PM
#2211   https://finance.yahoo.com/news/zynerba-pharmaceuticals-enters-oversold-territory dhbuzz 02/18/20 03:19:24 PM
#2210   I agree 100%,it is hard to watch,and the dhbuzz 02/15/20 07:52:36 AM
PostSubject